Breast Cancer
Conditions
Brief summary
This is a single-center, prospective, single arm phase II study to evaluate the efficacy and safety of nab-paclitaxel plus carboplatin (with trastuzumab for HER-2 positive patients) as neoadjuvant therapy in operable locally advanced breast cancer patients. The primary objective is pCR. The secondary objectives include ORR, 3-yr DFS, OS and safety. The sample size is 30.
Interventions
DRUGnab-paclitaxel
nab-paclitaxel 125mg/m2, day 1, 8, 15, q4w; carboplatin AUC 2, day 1, 8, 15, q4w; for HER-2 positive patients: trastuzumab loading dose 4mg/kg, then 2mg/kg, day 1, 8, 15, 22, q4w. All patients will receive up to four cycles except for unacceptable toxicity
Sponsors
Shanghai Cancer Hospital, China
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Female, between 18 and 70 years old * Life expectancy is more than 12 months * Breast MRI or ultrasound confirmd tumor over 3cm and biopsy comfirned invasive breast caner of stage II-III (inflammatory breast cancer excluded) * Not accompanied with other malignancies（except for controlled carcinoma in situ of the cervix or skin basal-cell carcinoma） * A normal bone marrow: absolute neutrophil count≥1.5\*10E9/L, hemoglobin≥100g/L, PLT≥100\*10E9/L * Normal liver and renal functions: AST≤60U/L, total biliruin≤1.5\*upper limit of normal, serum creatinine≤110umol/L, urea nitrogen≤7.1mmol/L * Normal blood coagulation function * ECOG performance status of 0-1 * Willing to coordinate with a punch biopsy before treatment and accept neoadjuvant therapy * Women of child-producing potential must agree to use effective contraceptive methods during the study, and a negative serum or urine pregnancy test must be obtained within 7 days prior to administration of the drugs * Written informed consent * For HER-2 positive patients, the HER-2 status must be determined by ICH +++ or FISH/CISH. For patients treated with trastuzumb, LVEF≥55% by ultrasonic cardiogram or MUGA scan
Exclusion criteria
* Previous systematic or local therapy including chemotherapy for breast cancer * Distant metastases of breast cancer are observed * Concurrent uncontrolled lung disease, severe sepsis, active peptic ulcer requring treatment, blood coagulation disorders, serious uncontrolled diabetes, connective tissue disease or bone marrow depression, unable to tolerate neoadjuvant therapy and related treatment * \>Grade 1 peripheral neuropathy caused by any reason * History of CHF, uncontrolled symptomatic angina, history of arrhythmias or myocardial infarction, poorly controlled hypertension (systolic pressure \> 180mmHg or diastlic pressure \> 100 mmHg) * Lactational or gestational breast cancer * Not willing to accept a punch biopsy before treatment and neoadjuvant therapy * Psychopath or any other reasons that would preclude compliane with treatment * Known serious allergy to any of the study drugs or excipients * Participation in another study requiring administration of an in investigational drug or biological agent at present or recently (within the last 30 days prior to screening visit)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pathological complete response rate | Obtained within six months of the last patient's enrollment | The percentage of patients with a pathological complete response after neoadjuvant therapy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall response rate | Obtained within six months of the last patient's enrollment | The percentage of patients with complete response or partial response after neoadjuvant therapy |
| Three-year disease free survival | Obtained within 42 months after last patient's enrollment | The percentage of patients who survive without breast cancer recurrence or metastases three years after surgery |
| Overall survival | Obtained around 5 years after the last patient's erollment | The overall survival time of all patients enrolled in the study presented by survival curve and median value |
| Safety | Obtained around six months after the last patient's enrollment | List and frequencies of adverse events occured during and one-month after the investigational drug treatment |
Countries
China
Outcome results
None listed